Lercanidipin Stada

Lercanidipine, the active ingredient in Lercanidipin Stada, is a dihydropyridine calcium channel blocker presented as an oral tablet for systemic use. It is indicated for the management of elevated blood pressure in adults, particularly those with essential hypertension.

GNH USA supplies Lercanidipin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is used to treat conditions within the hypertension disease family by relaxing vascular smooth muscle and lowering arterial pressure.

- Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Isolated systolic hypertension: improves pulse pressure in older patients. - Hypertension in the elderly: provides effective blood pressure control with once‑daily dosing.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often occurring early in therapy. - Flushing: warm sensation and reddening of the skin, usually transient. - Peripheral edema: swelling of the ankles or lower legs due to vasodilation. - Dizziness or light‑headedness, especially when standing quickly. - Tachycardia: increased heart rate as a reflex response.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Blood pressure monitoring: assess baseline and periodic readings to avoid excessive hypotension. - Hepatic impairment: use with caution and consider dose adjustment in patients with liver disease. - Elderly patients: start at the lowest effective dose due to increased sensitivity. - Concomitant antihypertensives: watch for additive blood‑pressure‑lowering effects. - Discontinuation: avoid abrupt cessation to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Grapefruit juice: can markedly raise drug levels and risk of hypotension. - Other potent antihypertensives: additive blood‑pressure‑lowering effect leading to severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Beta‑blockers: may require careful titration to avoid excessive heart‑rate reduction. - Diuretics: monitor electrolytes and blood pressure for synergistic effects.